KDM5-C70 NEW
| Price | $56 | $81 | $143 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: KDM5-C70 | CAS No.: 1596348-32-1 |
| Purity: 99.12% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | KDM5-C70 |
| Description | KDM5-C70 is an ethyl ester derivative of KDM5-C49 and functions as an effective, cell-permeable, pan-KDM5 histone demethylase inhibitor. It exhibits an antiproliferative effect in myeloma cells and induces a genome-wide elevation of H3K4me3 levels. |
| In vitro | KDM5-C70 (50 μM; 7 days; MM.1S myeloma cells) treatment reduces the level of phosphorylation of retinoblastoma protein (Rb) while leaving the total level of phosphorylated Rb (pRb) unchanged, indicating impairment of cell cycle progression. KDM5-C70 (1 nM-10 μM; 7 days; MM.1S myeloma cells) treatment displays antiproliferative effects after 7 days of treatment at elevated concentrations (estimated 50% reduction of viability/proliferation for KDM5-C70 at ~20 μM). Chromatin immunoprecipitation followed by next-generation sequencing displays an enhanced H3K4me3 level around transcription start sites with KDM5-C70 but little change with GSK467A at 50 μM inhibitor concentrations [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 250 mg/mL (743.10 mM), Sonication is recommended. |
| Keywords | KDM5-C70 | KDM5-C49 | Histone Demethylase | JARID1 | retinoblastoma | inhibit | KDM5 C70 | KDM-5-C70 | phosphorylation | KDM5C70 | KDM5 | Inhibitor | H3K4me3 | antiproliferative |
| Inhibitors Related | LSD1-IN-24 | Tranylcypromine hemisulfate | DDP-38003 dihydrochloride | GSK-LSD1 dihydrochloride | GSK-J4 | FY-21 | Daminozide | Zavondemstat | AS8351 | Procaine hydrochloride | JIB-04 | KDM4-IN-4 |
| Related Compound Libraries | Histone Modification Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1kg |
VIP5Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-10-13 | |
| $2500.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $49.60/1KG |
VIP4Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-07-31 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY